ROSSARI Rossari Biotech Q1 FY26 results (Apr–Jun 2025) and concall
Rossari Biotech delivered a steady Q1 FY26 performance with healthy top-line growth driven by HPPC and AHN segments, despite global headwinds impacting exports and the institutional business. The company is focused on capacity expansion, international footprint, and optimizing product mix, aiming for improved profitability and sustained growth from FY27 onwards. Management addressed Q1 softness due to plant shutdowns and remains confident in achieving break-even for the institutional business by next year.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|
| Revenue | 368 | 427 | 366 |
| EBITDA | 50 | 52 | 44 |
| Net profit | 31 | 32 | 26 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
